Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rowan E Miller

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Clinical Genitourinary Cancer|May 27, 2019
Body Mass Index and Outcomes in Germ-Cell TumorsBradley A McGregor, Rowan E Miller, Elizabeth O'Donnell, et al.
European Urology Focus|July 30, 2017
Age ≥40 Years Is Associated with Adverse Outcome in Metastatic Germ Cell Cancer Despite Appropriate Intended ChemotherapyRowan E Miller, Sarah C Markt, Elizabeth O'Donnell, et al.
Frontiers in Oncology|November 13, 2023
Seminoma and dysgerminoma: evidence for alignment of clinical trials and de-escalation of systemic chemotherapyGeorgina E Wood, Christopher P Bunting, Mesel Veli, et al.
The Oncologist|September 8, 2024
The impact of inter-cycle treatment delays on overall survival in patients with advanced-stage ovarian cancerLuke Steventon, Kenneth K C Man, Shibani Nicum, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2024
The impact of inter-cycle treatment delays on 5-year all-cause mortality in early-stage breast cancer: A retrospective cohort studyLuke Steventon, Emma Kipps, Kenneth Kc Man, et al.
Cancer|August 9, 2016
Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumorsSarah C Markt, Carlos A Lago-Hernandez, Rowan E Miller, et al.
JAMA Oncology|February 6, 2025
Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer: A Phase 2 Nonrandomized Clinical TrialRebecca Kristeleit, Michael-John Devlin, Andrew Clamp, et al.
British Journal of Cancer|May 17, 2025
The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa studyTimothy A Yap, Patricia LoRusso, Rowan E Miller, et al.
Cancer Research|November 19, 2013
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivityIlirjana Bajrami, Jessica R Frankum, Asha Konde, et al.
Cancers|November 9, 2024
Ethnicity and Socioeconomic Disparities in Clinical Trial Participation for Ovarian Cancer: A Retrospective Observational Study in LondonKarim H El-Shakankery, Joanna Kefas, Kieran Palmer, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Clinical Genitourinary Cancer|May 27, 2019
Body Mass Index and Outcomes in Germ-Cell TumorsBradley A McGregor, Rowan E Miller, Elizabeth O'Donnell, et al.
European Urology Focus|July 30, 2017
Age ≥40 Years Is Associated with Adverse Outcome in Metastatic Germ Cell Cancer Despite Appropriate Intended ChemotherapyRowan E Miller, Sarah C Markt, Elizabeth O'Donnell, et al.
Frontiers in Oncology|November 13, 2023
Seminoma and dysgerminoma: evidence for alignment of clinical trials and de-escalation of systemic chemotherapyGeorgina E Wood, Christopher P Bunting, Mesel Veli, et al.
The Oncologist|September 8, 2024
The impact of inter-cycle treatment delays on overall survival in patients with advanced-stage ovarian cancerLuke Steventon, Kenneth K C Man, Shibani Nicum, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2024
The impact of inter-cycle treatment delays on 5-year all-cause mortality in early-stage breast cancer: A retrospective cohort studyLuke Steventon, Emma Kipps, Kenneth Kc Man, et al.
Cancer|August 9, 2016
Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumorsSarah C Markt, Carlos A Lago-Hernandez, Rowan E Miller, et al.
JAMA Oncology|February 6, 2025
Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer: A Phase 2 Nonrandomized Clinical TrialRebecca Kristeleit, Michael-John Devlin, Andrew Clamp, et al.
British Journal of Cancer|May 17, 2025
The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa studyTimothy A Yap, Patricia LoRusso, Rowan E Miller, et al.
Cancer Research|November 19, 2013
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivityIlirjana Bajrami, Jessica R Frankum, Asha Konde, et al.
Cancers|November 9, 2024
Ethnicity and Socioeconomic Disparities in Clinical Trial Participation for Ovarian Cancer: A Retrospective Observational Study in LondonKarim H El-Shakankery, Joanna Kefas, Kieran Palmer, et al.
Pageof 4